【科源制药：股东问泽鸿拟减持不超过3%公司股份】科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。

金融界2025-05-25

科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2538456119?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-25 15:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538456119","market":"us","top_or_hot":-1,"title":"【科源制药：股东问泽鸿拟减持不超过3%公司股份】科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。","media":"金融界","content":"<div>\n<p>科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/25153950649777.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【科源制药：股东问泽鸿拟减持不超过3%公司股份】科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【科源制药：股东问泽鸿拟减持不超过3%公司股份】科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-25 15:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/05/25153950649777.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/25153950649777.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301281","symbol_name":"科源制药","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/05/25153950649777.shtml","article_id":"2538456119","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538456119","pubTimestamp":1748158799,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301281":"科源制药","BK0239":"医药制造"},"translate_title":"[Keyuan Pharmaceutical: Shareholder Wenzehong plans to reduce its holdings of no more than 3% of the company's shares] Keyuan Pharmaceutical announced that the company's shareholder Wenzehong plans to reduce its holdings of no more than 3,248,700 shares through centralized bidding and block trading, accounting for 3.00% of the company's total share capital. Among them, no more than 1,082,900 shares were reduced through centralized bidding transactions, accounting for 1.00% of the company's total share capital; Reduce its holdings by no more than 2,165,800 shares through block transactions, acc","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301281":1},"content_text":"科源制药公告称，公司股东问泽鸿计划以集中竞价及大宗交易方式减持公司股份不超过3,248,700股，占公司总股本的3.00%。其中，通过集中竞价交易方式减持不超过1,082,900股，占公司总股本的1.00%；通过大宗交易方式减持不超过2,165,800股，占公司总股本的2.00%。减持期间为公告发布之日起十五个交易日后的三个月内。减持价格将根据市场价格确定，且不低于发行价。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2538456119","isCrawlerRequest":true}